Mesothelioma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 4383
Special Issue Editor
Special Issue Information
Malignant mesothelioma is a disease affecting serosal surfaces derived from mesothelium comprising the pleura, peritoneum, pericardium, and tunica vaginalis testis. Peritoneal mesothelioma (PM) accounts for 7–30% of all cases
The most common diffuse malignant form of PM (DMPM) is characterized macroscopically by thousands of whitish tumor nodules of variable size and consistency that may coalesce to form plaques or masses or layer out uniformly to cover the entire peritoneal surface. Although there might be an association of asbestos exposure with DMPM, this disease's pathogenesis is mostly unknown. Patients usually present with advanced disease that causes abdominal pain or distension. As the disease progresses, patients die due to intestinal obstruction or terminal starvation within a year. In most patients, DMPM remains localized within the abdominopelvic cavity throughout its course. An intense activity of clinical and scientific research has allowed in the last two decades to improve the prognosis of patients through the introduction of innovative treatment modalities such as cytoreductive surgery (CRS) and hyperthermic intra peritoneal chemotherapy, and more recently the use of biological drugs and immunotherapy.
This Special Issue’s objective is to present a comprehensive overview of the state-of-the-art data regarding the epidemiology, diagnostics, therapeutics, and pathophysiology of PM.
The current project brings together the efforts of the most prominent experts in peritoneal surface oncology and has the mission to provide clinicians and researchers worldwide with a updated information that will serve to optimize therapeutics further, improve prognosis, and deepen our knowledge of the disease’s biology in the years to come.
Dr. Marcello Deraco
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Malignant
- Malignant mesothelioma
- Peritoneal mesothelioma (PM)
- cytoreductive surgery (CRS)
- Cancer
